Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Charles Craddock

Showing results (31-40 of 165) with videos related to

Pageof 17
Sort By:
Lancet (London, England)|March 19, 2002
Survival after bone-marrow transplantationKate Cwynarski, Charles Craddock, Mark Cobbold, et al.
Blood Reviews|April 9, 2021
AML and the art of remission maintenanceMarcos de Lima, Gail J Roboz, Uwe Platzbecker, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 15, 2025
Guidance for <i>JCO</i> Authors on Subgroup Representation and ReportingStephanie B Wheeler, Alexia Iasonos, Iona Cheng, et al.
British Journal of Haematology|April 11, 2024
Strategies to reduce relapse risk in patients undergoing allogeneic stem cell transplantation for acute myeloid leukaemiaFrancesca A M Kinsella, Maria A L Maroto, Justin Loke, et al.
Therapeutic Drug Monitoring|March 13, 2010
Prediction of intravenous cyclosporine area under the concentration-time curve after allogeneic stem cell transplantationNicholas Duncan, Julie Arrazi, Sandeep Nagra, et al.
Haematologica|May 16, 2015
Characterization of CMV-specific CD4+ T-cell reconstitution following stem cell transplantation through the use of HLA Class II-peptide tetramers identifies patients at high risk of recurrent CMV reactivationMohammad Raeiszadeh, Annette Pachnio, Jusnara Begum, et al.
British Journal of Haematology|November 13, 2019
Characteristics of graft-versus-host disease occurring after alemtuzumab-containing allogeneic stem cell transplants: incidence, organ involvement, risk factors and survivalMaria C Finazzi, Cristina Boschini, Charles Craddock, et al.
Blood|May 3, 2002
Imatinib mesylate (STI571) in the treatment of relapse of chronic myeloid leukemia after allogeneic stem cell transplantationEduardo Olavarria, Charles Craddock, Francesco Dazzi, et al.
Frontiers in Immunology|December 19, 2022
CMV reactivation initiates long-term expansion and differentiation of the NK cell repertoireNorfarazieda Hassan, Suzy Eldershaw, Christine Stephens, et al.
BMJ Open|January 29, 2014
Stratified medicine in European Medicines Agency licensing: a systematic review of predictive biomarkersKinga Malottki, Mousumi Biswas, Jonathan J Deeks, et al.
Pageof 17

Showing results (31-40 of 165) with videos related to

Sort By:
Pageof 17
Lancet (London, England)|March 19, 2002
Survival after bone-marrow transplantationKate Cwynarski, Charles Craddock, Mark Cobbold, et al.
Blood Reviews|April 9, 2021
AML and the art of remission maintenanceMarcos de Lima, Gail J Roboz, Uwe Platzbecker, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 15, 2025
Guidance for <i>JCO</i> Authors on Subgroup Representation and ReportingStephanie B Wheeler, Alexia Iasonos, Iona Cheng, et al.
British Journal of Haematology|April 11, 2024
Strategies to reduce relapse risk in patients undergoing allogeneic stem cell transplantation for acute myeloid leukaemiaFrancesca A M Kinsella, Maria A L Maroto, Justin Loke, et al.
Therapeutic Drug Monitoring|March 13, 2010
Prediction of intravenous cyclosporine area under the concentration-time curve after allogeneic stem cell transplantationNicholas Duncan, Julie Arrazi, Sandeep Nagra, et al.
Haematologica|May 16, 2015
Characterization of CMV-specific CD4+ T-cell reconstitution following stem cell transplantation through the use of HLA Class II-peptide tetramers identifies patients at high risk of recurrent CMV reactivationMohammad Raeiszadeh, Annette Pachnio, Jusnara Begum, et al.
British Journal of Haematology|November 13, 2019
Characteristics of graft-versus-host disease occurring after alemtuzumab-containing allogeneic stem cell transplants: incidence, organ involvement, risk factors and survivalMaria C Finazzi, Cristina Boschini, Charles Craddock, et al.
Blood|May 3, 2002
Imatinib mesylate (STI571) in the treatment of relapse of chronic myeloid leukemia after allogeneic stem cell transplantationEduardo Olavarria, Charles Craddock, Francesco Dazzi, et al.
Frontiers in Immunology|December 19, 2022
CMV reactivation initiates long-term expansion and differentiation of the NK cell repertoireNorfarazieda Hassan, Suzy Eldershaw, Christine Stephens, et al.
BMJ Open|January 29, 2014
Stratified medicine in European Medicines Agency licensing: a systematic review of predictive biomarkersKinga Malottki, Mousumi Biswas, Jonathan J Deeks, et al.
Pageof 17